The aim of this study was to investigate whether quantitative CT image-biomarkers (IBMs) can improve the prediction models with only classical prognostic factors for localcontrol (LC), regional-control (RC), distant metastasis-free survival (DMFS) and diseasefree survival (DFS) for head and neck cancer (HNC) patients.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is primarily managed by surgery and/ or radiotherapy (RT) with or without systemic treatment. At present, the 5-year overall survival rate is around 60% [1] . However, 30%-50% of patients with locally advanced HNSCC still experience treatment failures, predominantly occurring at the site of the primary tumor, followed by regional failures and distant metastases [2] . Risk assessment of local control (LC), regional control (RC), distant metastasis-free survival (DMFS) and disease-free survival (DFS) of HNSCC patients becomes increasingly important to optimise treatment [3] [4] [5] [6] [7] . For HNSCC patients, molecular-based factors such as human papillomavirus (HPV) [3, 4] and patient-specific factors such as age and World Health Organization performance-status (WHO PS) have been identified as prognostic clinical factors for LC, RC, DMFS and DFS [5] [6] [7] . However, these clinical factors are not sufficient for identifying patients that will benefit most from specific treatment strategies. For this purpose, more detailed information is required, including factors that reflect the characteristics of the whole tumor, such as tumor volume, shape and heterogeneity [8] [9] [10] [11] [12] [13] [14] [15] [16] .
A wide variety of medical images is generated for diagnostic and staging purposes, such as TNM staging. In current clinical practice, these images are used for guiding treatment decision-making [3] . Image-biomarkers (IBMs) may also be extracted from these medical images, transforming image data into quantitative information that describes intensity, shape and textural characteristics of the whole tumor. IBMs can provide more spatial and textural information about tumor features than TNM staging [8] [9] [10] . For patients treated with primary non-surgical modalities, like (chemo)radiotherapy, where only limited pathological information is available, the use of image-biomarkers might improve the prediction of treatment outcomes and improve medical decision-making [9] .
IBMs have demonstrated their value to predict treatment outcome and complications for patients with head and neck, lung, breast, pancreatic, and colorectal cancers [9, [11] [12] [13] [14] [15] [16] . In a previous study, we showed that the quantitative computed-tomography (CT) IBMs were good substitutes for the qualitative clinical variable N-stage, and that they improved the performance of multivariable prediction models for overall survival, compared to models consisting of clinical variables alone [17] . The next challenge is to find IBMs that allow for a better prediction of local-regional failure and distant metastasis. Based on our previous study, we hypothesized that IBMs would provide similar or better predictive information than clinical variables for LC, RC, DMFS and DFS.
The aim of this study was to investigate whether multivariable prediction models for LC, RC, DMFS and DFS, consisting of both clinical variables and IBMs perform better than prediction models with only classical prognostic factors.
Materials and Methods

Patient selection and treatment
This was a retrospective analysis in a prospective cohort study, which was composed of 707 consecutive non-surgically treated HNSCC patients. The tumors originated in the oral cavity, oropharynx, nasopharynx, hypopharynx or larynx and were primarily treated with definitive radiotherapy at the University Medical Center Groningen between July 2007 and December 2015. We excluded 202 patients without contrast-enhanced planning CTscans, 45 patients with metal or motion artifacts in the region of the primary tumor (PT) or positive lymph nodes (LN), and 16 patients with previous neck dissection. Overall 444 patients with standard contrast-enhanced planning CT-scans (Somatom Sensation Open, Siemens, Forchheim, Germany; voxel size: 1.0×1.0×2.0 mm; scan voltage: 120kV; and convolution kernel: B30) were included. Overall 240 patients treated before June 2012 were enrolled in the training cohort and 204 patients treated after June 2012 in the validation cohort. All patients were treated with definitive three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT) to a total dose of 70 Gy with fractions of 2 Gy in 6-7 weeks, with or without chemotherapy or cetuximab. Detailed radiation protocols have been published previously [17, 18] .
Clinical parameters
Clinical parameters including age, gender, TNM-stage, clinical stage, treatment modality and WHO PS were collected from our prospective data registration program. TNM and clinical stage were defined according to the 7th edition of the American Joint Committee on Cancer Staging Manual [3] . Tumor site was included in the analysis, and tumors originating in the oropharynx were further stratified by HPV status as HPVpositive, HPV-negative and HPV-unknown (Table 1) . HPV-status was assessed by p16 
CT image-biomarkers
An overview of the IBM extraction process and analysis is shown in Fig. 1 . The IBMs were extracted using in-house developed Matlab based software (version R2014a; Mathworks, Natick, USA). For a more detailed description of the IBMs, we refer to previous work [11] and Supplementary A. All IBMs were reported complying with th REMARK guidelines [18] and IBM formulas are in line with the "Image biomarker standardisation initiative" [10] .
CT intensity and geometric IBMs
The primary tumor (PT) and pathological lymph node (LN) were delineated on the planning CT-scans by experienced head and neck radiation oncologists. Thirty-six intensity and 40 geometric IBMs were extracted from both the PT and LN. All IBMs from LN were marked as LN_IBMs. The intensity IBMs were obtained from the histogram of the voxel intensities of the delineated structures, e.g. mean represents the average voxel intensity and the skewness quantifies the degree of asymmetry around the mean value.
The geometric IBMs, such as volume, bounding-box-volume and major-axis-length, were extracted from the three-dimensional (3D) contoured structures. The LN_IBMs from patients without lymph node metastasis were defined as 0.
CT textural IBMs
Forty-four textural CT IBMs describing the radiological heterogeneity of the PT tissue were derived from three different matrices: the gray level co-occurrence matrix (GLCM) [20] , the gray level run-length matrix (GLRLM) [21] and the gray level size-zone matrix (GLSZM) [22] . Those matrices provide a statistical view of image texture based on the relationship between neighbouring pixels. GLCM IBMs describe the number of voxel transitions of certain gray levels, e.g. the IBM correlation is larger in case of larger areas of similar gray levels. GLRLM IBMs assess the number of directional gray level repetition, e.g. low run length non-uniformity means consecutive voxels with the same gray level are distributed homogeneously. The GLCM and GLRLM IBMs were computed from each 3D directional matrix and averaged over 13 directions. GLSZM quantifies the volumetric gray level repetition, e.g. small zone emphasis depends on the occurrence of small zone.
A higher value indicates to the fine texture and a lower value corresponds to the coarse texture. GLSZM IBMs were computed from a 3D matrix.
Endpoints
The endpoints were LC, RC, DMFS and DFS. The events of LC and RC were defined as recurrent or residual disease within or adjacent to the primary site and regional nodes, respectively. The events of DMFS were defined as distant metastasis. Events for DFS is defined as any events mentioned above or death due to any causes. Time to event was defined as the date from the first day of radiotherapy until the date of the event.
Patients without failures were censored at the date of last follow-up. Patients received systematic follow-up every 3 months in the first year following treatment and every 6 months thereafter.
Data analysis
Step 1: Clinical models Step 2: IBM models Twenty patients from the training cohort were used for the evaluation of the inter-and intra-observer reproducibility. For each patient, the IBMs were extracted from two delineations by two radiation oncologists and two delineations within 6 months by one radiation oncologist. The interclass correlation coefficient (ICC) of IBMs larger than 0.70 were considered to be robust for delineation variation, and were included in the further analysis.
To reduce the probability of overfitting and multicollinearity, pre-selection was performed for IBMs. All IBMs were analyzed as continuous variables, if the Spearman rank correlation (ρ) between pairs of IBMs was > 0.80, then the IBM with the lower univariable association with the endpoint was excluded from further analysis [23, 24] .
After pre-selection, multivariable Cox proportional hazard regression analysis was used to develop multivariable IBM models.
The entire process of pre-selection and model development was repeated in 1000 bootstrap samples, and only the most frequently selected variables were included in the final IBM models. The same methodology was used for combined models described below.
Step 3: Combined models All clinical factors and IBMs were included in the multivariable analysis to create combined models. The same bootstrapping methodology including pre-selection and model development described in step 2 was used to build final combined models.
Step 4: Model performance in the training and validation cohorts
The concordance index (c-index) was determined to assess the models' discriminative power and the z-score test was used to test the significance of c-index differences.
Internal validation (bootstrapping) was used for the variable selection, and accordingly correction for optimism of coefficients and c-indexes according to the TRIPOD statement [25] .
The performance of the corrected final clinical, IBM and combined models were then tested in the validation cohort. Patients in the validation cohort were stratified into two risk groups based on the models: a low-risk group with hazard values ≤ the median and a high-risk group with hazard values > the median. Kaplan-Meier curves were generated to analyze LC, RC, DMFS and DFS rates for the low-and high-risk groups and Log-rank tests were used to compare the differences.
The chi-square test was used to compare the categorical variables and an independent sample t-test was used to compare normally distributed variables between different groups. Two tailed p-values <0.05 were considered statistically significant. Statistical analysis was performed using the R software (version 3.2.1). The R-package survival (version 2.41-3) was used for modeling.
Results
For the training cohort, the median follow-up times for LC, RC, DMFS and DFS were 48.2, 49.7, 50.3 and 45.2 months, respectively. Overall, 56 (23%) local recurrences, 38 (16%) regional recurrences, 34 (14%) distant-metastases and 137 (57%) events occurred for LC, RC, DMFS and DFS. For the validation cohort, the median follow-up times for LC, No significant differences between the two datasets were found regarding the baseline characteristics.
Step 1: Clinical models Univariable analysis showed weak associations between tumor site (combined with HPV status) and endpoints. Therefore, the variable tumor site was analysed as a composite variable by combining different tumor sites. Similar associations with the endpoints were found for nasopharyngeal cancer, HPV-positive OPC and laryngeal cancer in this cohort, which is in line with the results of other studies [26] [27] [28] . Hence, tumor sites with A number of other clinical parameters showed significant associations with outcomes in the univariable analysis. They are shown in Supplementary B.
In the multivariable clinical analysis ( Table 2) , composite tumor site was identified as an independent significant prognostic feature for LC, DMFS and DFS. Next to composite tumor site, WHO PS was associated with LC, and clinical stage and WHO PS were associated with RC. N-stage was a significant prognostic factor for DMFS, while WHO PS and age were associated with DFS.
Step 2: IBM models
The average of the inter-and intra-observer agreement of all IBMs was 0.90 and 0.88, showing the stability of contouring was reasonably good. The ICC value for the interobserver and intra-observer agreement was higher than 0.7 for 91% and 89% of the radiomic features and only the IBMs with an ICC > 0.7 were included in the further analysis.
According to the variable selection frequency plot (Supplementary C), the following IBMs were most frequently selected and significantly associated with the endpoints in the multivariable analyses for LC: correlation of GLCM; for RC and DMFS: bounding-boxvolume and LN_major-axis-length, and for DFS: bounding-box-volume and correlation of GLCM (Table 2) .
Step 3: Combined models
The coefficients and variables of the final combined models are depicted in Table 2 .
Composite tumor site and correlation of GLCM were selected with a comparable frequency as independent prognostic factors for the combined LC and DFS models (Frequency plot in Supplementary C). Correlation of GLCM was found to be significantly associated with composite tumor site (p < 0.001, logistic regression analysis), therefore any one of these could be included in the model, and performed similarly. For this study, only the feature with the larger frequency was included in the combined model. with the combined models ( Fig. 3b,d,f,h) , the differences between the curves were larger than with all clinical models (Fig. 3a,c, 
Discussion
This study showed a detailed analysis on the different patterns of failure by evaluating LC, RC, DMFS and DFS for HNC patients primarily treated with radiotherapy. Firstly, all clinical variables were explored thoroughly to build optimal clinical models for comparison [29] . Secondly, the quantitative IBMs were included in the models and provided similar information as qualitative clinical variables. Finally, combined models showed slightly better performance or as good performance as clinical and IBM models in this study.
Clinical models were developed based on clinical parameters alone. HPV status, as a confirmed significant prognostic factor in OPC patients, was combined with tumor site in the analysis [4, 27, 28] (Table 1) . However, no strong associations between tumor site and endpoints were found in the univariable analysis. In order to obtain the optimal clinical models, the composite tumor sites with similar associations with endpoints were grouped together, and showed significant associations with LC, RC, DMFS and DFS [2, 4, 7, 26] . The other clinical prognostic factors (WHO PS, clinical stage, N-stage and age) in our study are in line with those found by other investigators [27] [28] [29] [30] [31] [32] [33] . Table 2 ).
Since tumor volume was a prognostic factor for overall survival for HNSCC patients with advanced stage, tumor volume was also included in the analysis as a geometric IBM [5, 8, 34, 35] . Tumor volume was a significant prognostic factor in the univariable analysis for RC, DMFS and DFS. It was strongly correlated with bounding-box-volume (ρ = 0.95), but performed slightly worse than bounding-box-volume in predicting RC, DMFS and DFS in this study. The difference between the bounding-box-volume and tumor volume is that bounding-box-volume includes information on both tumor volume and shape ( Fig.   4a and b). The tumor volumes in Fig. 4a and Fig. 4b were similar, but the bounding-boxvolume of Fig. 4b had an irregular shape, and was twice as large as that of Fig. 4a . Tumor volume depends on the doubling time of tumor cells, while tumor shape is caused by invasive growth patterns. Our result suggests that the bounding-box-volume is more relevant for the RC and DFS than tumor volume.
LN_major-axis-length describes the largest distance between any two voxels of the positive lymph node(s) ( Fig. 4c and d) , which is the most selected IBM of RC and DMFS IBM models (Supplementary C). When the patient has only one lymph node, LN_major- Fig. 4. Examples of patients with low (a,c,e) and high (b,d,f) values of bounding-box-volume, LN_major-axislength and correlation of GLCM. Abbreviation: GLCM: gray level co-occurrence matrix.
axis-length represents the size of the LN. When the patient has more than 1 lymph node, it means the largest distance between two distant lymph nodes. A larger LN_major-axis length is not only related to the size of the pathological lymph nodes but also to the distance between them, which might indicate more aggressive behavior of the tumor cells. LN_major-axis-length showed a spearman rank correlation of 0.80 with N-stage.
However, LN_major-axis-length performed better than N-stage in the prediction of RC and DMFS, and N-stage did not add prognostic information to the model with LN_majoraxis-length. This observation was supported by our previous study on overall survival, in which LN_major-axis-length had a stronger association with overall survival than N-stage [17] . The LN_major-axis length reflects not only N-stage information (size and location) but also patterns of growth. Therefore, it is advantageous to use LN_major-axis length as a surrogate for N-stage.
Correlation was selected as a prognostic IBM for LC and DFS. A lower correlation value indicates a higher radiological homogeneity, which was associated with improved LC and DFS in our study ( Fig. 4e and f [17, 20, 36] . There are other IBMs which are also used to quantify the intra-tumor heterogeneity and homogeneity on a millimeter scale, such as run length non-uniformity and gray level non-uniformity. These IBMs demonstrate prognostic performance for overall survival in HNC [9, 17] . The intra-tumor heterogeneity is caused by multiple coexisting sub-clonal populations in the tumor [36, 37] . The association between cellular information and IBMs may explain the performance of IBMs in survival analysis. Further research is necessary to investigate the underlying mechanisms and to identify IBMs representing tumor radiological heterogeneity for different endpoints. Our study found that the correlation of GLCM was significantly associated with the composite tumor site (p < 0.001). This association could be explained by the higher homogeneous tissue density in HPV-positive OPC, laryngeal and nasopharyngeal cancers, compared with other tumor sites. This hypothesis should be explored and these models might be improved with the addition of subgroup analysis in different head and neck tumor locations.
The advantage of using IBMs is that they provide quantitative and objective information compared with traditional medical image analysis. Furthermore, on the basis of noninvasive medical imaging, IBMs could be used to assess the characteristics of tumor tissue.
In this study, it was shown that CT IBMs performed as well as clinical features in predicting treatment outcomes. It is expected that IBMs extracted from more advanced imaging techniques would provide more tumor-specific information. Therefore, more studies on IBMs from advanced imaging techniques is recommended, to improve risk stratification for HNSCC. However, the variations in imaging protocols, segmentation, feature selection and modelling between different institutes may reduce the reproducibility, robustness and clinical utility. Standardization of the extraction of IBMs and report guidelines have been proposed and must be followed [29] . Furthermore, validation of IBMs on large external datasets is needed to ensure widespread acceptance.
The prediction models we described can be used to identify patients with a high risk of recurrence and metastasis prior to definitive (chemo-)radiation. Close imaging follow up for high risk patients after treatment can be suggested in cases when salvage surgery is applicable. Furthermore, dose intensification and more aggressive adjuvant treatment are options for high risk patients. These options should be investigated in order to guide future personalized strategies aimed at improving treatment outcome. Whether this model is applicable to HNC patients treated with surgery is not discussed in this paper.
Conclusion
Models containing quantitative image-biomarkers describing the volume, irregular shape and radiological heterogeneity of the tumor and the distance between lymph nodes performed as good as clinical variables in predicting treatment outcomes for HNC patients. These image-biomarkers are worth exploring in future studies to determine whether they can improve the clinical approaches currently employed.
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